PRINT THIS PAGE

The Nordic life sciences investment opportunity

The Nordic region is home to approximately 22 per cent of all European entrepreneurial life sciences companies. As a result, there is a substantial need for capital and experienced management teams in the immediate future says Leif Helth Jensen of Danske Life Science.

Medicon Valley is the most concentrated life sciences area in the Nordic region, with over 26 university hospitals, five science parks, 12 universities and 135,000 students. It is not surprising that Denmark, Sweden and Finland have the second highest R&D expenditure per capital and the third highest government-financed R&D expenditure per capita of all OECD countries.

Click here to view full report (pdf 120kb)

You need Adobe Acrobat to read this document. If you do not have it, you can download it free from www.adobe.com/products/acrobat/readstep.html

The Nordic region ranks as one of the leading life sciences regions in the world, with important clusters in Denmark, Sweden and Finland. The depth and breadth of scientific knowledge, combined with the presence of a large number of major pharmaceutical and biotechnological companies, create a solid foundation for the life sciences industry. A stimulating platform for value creation is thus already in place, and together with a capable, complementary and dedicated team represents an attractive investment proposition. Danske Life Science with a target size of E150 m is being established to take advantage of the existing and expected investment opportunities. The objective is to generate outstanding financial returns by sourcing, evaluating, selecting, actively developing and finally realising a portfolio of life sciences companies.